Technology
Health
Pharmaceutical

AcelRx Pharmaceuticals

$2.84
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.11 (3.94%) Today
-$0.06 (-2.07%) After Hours

Why Robinhood?

You can buy or sell ACRX and other stocks, options, ETFs, and crypto commission-free!

About

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. Its products include sufentanil, DZUVEO, DSUVIA ZALVISO US and ZALVISO EU. Read More The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Redwood City, CA.

Employees
61
Headquarters
Redwood City, California
Founded
2005
Market Cap
228.68M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
2.14M
High Today
$2.93
Low Today
$2.76
Open Price
$2.79
Volume
945.46K
52 Week High
$5.05
52 Week Low
$1.99

Collections

Technology
Health
Pharmaceutical
US
North America

News

Yahoo FinanceMay 9

Edited Transcript of ACRX earnings conference call or presentation 8-May-19 8:30pm GMT

Q1 2019 AcelRx Pharmaceuticals Inc Earnings Call REDWOOD CITY May 9, 2019 (Thomson StreetEvents) -- Edited Transcript of AcelRx Pharmaceuticals Inc earnings conference call or presentation Wednesday, May 8, 2019 at 8:30:00pm GMT TEXT version of Transcript ================================================================================ Corporate Participants ================================================================================ * Pamela Pierce Palmer AcelRx Pharmaceuticals, Inc. - Co-Founder...

615
Yahoo FinanceMay 8

AcelRx Pharmaceuticals Reports Q1 Loss, Lags Revenue Estimates

AcelRx Pharmaceuticals (ACRX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.23 per share a year ago.

315
PR NewswireMay 8

AcelRx Pharmaceuticals Reports First Quarter 2019 Financial Results

REDWOOD CITY, Calif., May 8, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its first quarter 2019 financial results. "I am very pleased with the progress made in the first five weeks of the DSUVIA™ launch. Shifting the paradigm in healthcare facilities to a new, non-invasive treatment option for acute pain will tak...

825

Earnings

-$0.28
-$0.24
-$0.21
-$0.17
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.22 per share
Actual
-$0.17 per share

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.